Obeticholic Acid D5 (2,2,3,4,4-d5)

Obeticholic Acid D5 is a deuterated analogue of Obeticholic Acid, which is a medication used to treat patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). PBC is an autoimmune disease that affects the liver, leading to chronic inflammation, scarring, and ultimately liver failure. NASH, on the other hand, is a type of non-alcoholic fatty liver disease that can lead to inflammation and scarring of the liver. Obeticholic Acid D5 works by binding to farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid synthesis and transport. By activating FXR, Obeticholic Acid D5 reduces the production and accumulation of toxic bile acids in the liver, which can lead to improved liver function and reduced inflammation. As a deuterated analogue of Obeticholic Acid, Obeticholic Acid D5 contains five deuterium atoms, which replace five hydrogen atoms. This modification enhances the pharmacokinetic properties of the drug, including improved metabolic stability, decreased clearance, and increased half-life. Obeticholic Acid D5 is typically administered orally in the form of tablets, and the recommended dosage varies depending on the patient's condition and medical history. Like all medications, Obeticholic Acid D5 may cause side effects, including nausea, headache, fatigue, and itching. Patients should consult their healthcare provider before taking Obeticholic Acid D5 and report any adverse reactions or concerns.